NGVT as reported
Ingevity Corporation reported $1.21B of revenue over the trailing twelve months, −2.0% on the year before. 11 reported series are charted on this page, each one as filed.
$1.21B
Revenue, trailing twelve months · to Q1 2026 · −2.0% against the twelve months before
- Net Income
- −$128M
Net Income · −64% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $246M
Free Cash Flow · +158% year on year · trailing twelve months to Q1 2026
- EPS
- −$3.52
EPS · −64% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.21B | −2.0% | Q1 2026 |
| Net Income | −$128M | −64% | Q1 2026 |
| EPS | −$3.52 | −64% | Q1 2026 |
| Gross Margin | 39% | n/a | Q1 2026 |
| Op Margin | 33% | n/a | Q4 2024 · 5 quarters behind |
| Net Margin | −9.3% | n/a | Q1 2026 |
| ROE | −280% | n/a | Q1 2026 |
| ROA | −8.2% | n/a | Q1 2026 |
| ROIC | 19% | n/a | Q4 2024 · 5 quarters behind |
| Free Cash Flow | $246M | +158% | Q1 2026 |
| P/E | 13.1 | n/a | Q3 2023 · 10 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ingevity Corporation (NGVT) - Revenue & ProfitRevenue & ProfitIngevity Corporation (NGVT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Specialty Chemicals
Ranks #7 of 36 by Smart Score